Matriptase is highly upregulated in chronic lymphocytic leukemia and promotes cancer cell invasion

Leukemia

Volumn 27, Issue 5, 2013, Pages 1191-1194

  Gao, L ^a   Liu, M ^a   Dong, N ^a   Jiang, Y ^a   Lin, C Y ^b   Huang, M ^c,d   Wu, D ^a   Wu, Q ^a,d,e  

^a SOOCHOW UNIVERSITY   (China)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER   (China)

^d Danish Chinese Center of Proteases and Cancer   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE MARKER; MATRIPTASE; SHORT HAIRPIN RNA;

BONE MARROW; CANCER CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; RNA, MESSENGER; SERINE ENDOPEPTIDASES; UP-REGULATION;

EID: 84877588729     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.289     Document Type: Letter

References (15)

1. Lin CY, Tseng IC, Chou FP, Su SF, Chen YW, Johnson MD et al. Zymogen activation, inhibition, and ectodomain shedding of matriptase. Front Biosci 2008; 13: 621-635.
2. Szabo R, Bugge TH. Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu Rev Cell Dev Biol 2011; 27: 213-235.
3. Kilpatrick LM, Harris RL, Owen KA, Bass R, Ghorayeb C, Bar-Or A et al. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 2006; 108: 2616-2623.
4. Darragh MR, Bhatt AS, Craik CS. MT-SP1 proteolysis and regulation of cell-microenvironment interactions. Front Biosci 2008; 13: 528-539.
5. List K. Matriptase: a culprit in cancer? Future Oncol 2009; 5: 97-104.
6. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 2005; 19: 1934-1950.
7. Kim C, Lee HS, Lee D, Lee SD, Cho EG, Yang SJ et al. Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration. Blood 2011; 117: 1415-1424.
8. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/ plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-36725.
9. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J et al. A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 2010; 70: 9631-9640.
10. Bugge TH, Antalis TM, Wu Q. Type II transmembrane serine proteases. J Biol Chem 2009; 284: 23177-23181.
11. Baba T, Kawaguchi M, Fukushima T, Sato Y, Orikawa H, Yorita K et al. Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells invasiveness. J Pathol 2012; 228: 181-192.
12. Xu H, Xu Z, Tseng IC, Chou FP, Chen YW, Wang JK et al. Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1. Am J Physiol Cell Physiol 2012; 302: C453-C462.
13. Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S et al. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem 2003; 278: 36341-36349.
14. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
15. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7: 800-808.